Fina Biosolutions
Exhibitor
About FinaBio
Fina Biosolutions is a privately held research and development-stage biotechnology company that discovers, develops, and collaborates to commercialize novel vaccine conjugates for the prevention of life-threatening diseases. FinaBio has patented novel techniques to conjugate, purify, and manufacture conjugates using its proprietary chemistry to create complex conjugate vaccines. The technology is currently licensed by leading vaccine manufacturers in both Europe and Asia, including GlaxoSmithKline for marketed vaccines Synflorix™, Nimenrix™, The Serum Institute of India, Pvt., Ltd. (SIIPL) vaccine Pneumosil® and MenFive®, The Chengdu Institute of Biological Products Co., Ltd (CDIBP) China, and others. We use our FinaXpress™ strain to produce conjugate carrier proteins, including EcoCRM®(CRM197) and 8MTT, a genetically detoxified full-length tetanus toxin. EcoCRM® is produced as a GMP product. The FinaXpress™ E. coli strain expresses disulfide-bonded proteins as properly folded, soluble, cytoplasmic proteins at high levels.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events